FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to a pharmaceutical composition containing an isolated antibody or its antigen-binding fragment, which specifically binds to alpha-toxin (AT) S.aureus, and recovered antibody or its antigen-binding fragment, which specifically binds to antigen S.aureus, which is a surface determinant selected from a group consisting of IsdH and ClfA. Also disclosed is a method of treating an infection S.aureus using said composition, a method of reducing bacterial agglutination S.aureus using said composition.
EFFECT: invention has the ability effectively treat infections S.aureus.
9 cl, 11 ex, 7 tbl, 18 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS OF ANTIBODIES TO STAPHYLOCOCCUS AUREUS | 2019 |
|
RU2804815C2 |
| ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS LEUKOTOXINS | 2019 |
|
RU2805969C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| STAPHYLOCOCCUS AUREUS CLUMPING FACTOR A (ClfA) ANTIBODY | 2019 |
|
RU2818805C2 |
| ANTI-ROR1/ANTI-CD3 BISPECIFIC BINDING MOLECULES | 2020 |
|
RU2831608C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| BISPECIFIC ANTIBODIES TO CCL2 | 2020 |
|
RU2819613C1 |
| ANTIBODIES BINDING TO GPRC5D | 2020 |
|
RU2841523C2 |
| SARS-CoV-2 ANTIBODIES AND METHODS OF USE THEREOF | 2021 |
|
RU2832025C1 |
